Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

TARSILA-studien om verklig evidens (TARSILA)

2 november 2026 uppdaterad av: Maicon Falavigna, Inova Medical

Real-world Effectiveness of maTernAl RSVpreF vaccInation Against RSV-associated Acute Respiratory ilLness in Infants in BrAzil (TARSILA Study): a Multicentre, Prospective, Test-negative, Case-Control Study

The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.

Studieöversikt

Detaljerad beskrivning

Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.

Studietyp

Observationell

Inskrivning (Beräknad)

5000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Paraná
      • Cascavel, Paraná, Brasilien, 85818-130
        • Rekrytering
        • Unidade de Pronto Atendimento Veneza
        • Kontakt:
      • Curitiba, Paraná, Brasilien, 80060-900
        • Rekrytering
        • Complexo do Hospital de Clínicas da Universidade Federal do Paraná
        • Kontakt:
        • Huvudutredare:
          • Cristina de Oliveira Rodrigues
      • Curitiba, Paraná, Brasilien, 80240-031
        • Rekrytering
        • Hospital Infantil Pequeno Príncipe
        • Kontakt:
        • Huvudutredare:
          • Heloisa Ihle Garcia Giamberardino
      • Marechal Cândido Rondon, Paraná, Brasilien, 85960-000
        • Rekrytering
        • Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
        • Kontakt:
      • Palotina, Paraná, Brasilien, 85950-000
        • Rekrytering
        • Unidade de Saúde Central de Palotina
        • Kontakt:
      • Toledo, Paraná, Brasilien, 85902-480
        • Rekrytering
        • Unidade de Pronto Atendimento II de Toledo
        • Kontakt:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 91350-200
        • Rekrytering
        • Hospital Nossa Senhora da Conceição
        • Kontakt:
        • Huvudutredare:
          • Fernanda H Varela
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
        • Rekrytering
        • Hospital de Clínicas de Porto Alegre
        • Kontakt:
        • Huvudutredare:
          • Ricardo Becker Feijó

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Inte äldre än 11 månader (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Infants with acute respiratory illness (ARI)

Beskrivning

Tarsila Inpatient Study

Inclusion Criteria

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Maternal or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Infant previously enrolled in this study.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.

Tarsila Outpatient Study

Inclusion Criteria:

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Mother or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.
  • Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_CONTROL
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Cases

Infants with a positive respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Controls

Infants with a negative respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing).

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
Tidsram: Occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Occurring ≤180 days after birth.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) .

Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
Tidsram: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness.

ARI occurring ≤180 days after birth

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization

RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization.

Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) .

Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.

RT-qPCR-confirmed RSV-positive LRTD in-hospital death.

Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization.

Hospitalization occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsram: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed HMPV-positive LRTD hospitalization

Hospitalization occurring ≤180 days after birth
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
Tidsram: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
ARI occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
Tidsram: ARI occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness.

ARI occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
Tidsram: LRTD occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤180 days after birth.
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
Tidsram: LRTD occurring ≤360 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤360 days after birth.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Maicon Falavigna, Inova Medical

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

27 april 2026

Primärt slutförande (Beräknad)

30 september 2028

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

20 februari 2026

Först inskickad som uppfyllde QC-kriterierna

25 februari 2026

Första postat (Faktisk)

3 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera